Koster Kira-Lee, Appenzeller Christina, Lauber Arno, Früh Martin, Schmid Sabine
Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Department of Radiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Case Rep Oncol. 2022 Aug 26;15(2):720-725. doi: 10.1159/000525341. eCollection 2022 May-Aug.
Treatment with sotorasib has shown intracranial complete responses and continued intracranial stabilization in mutated non-small-cell lung carcinoma (NSCLC) patients with previously treated, stable brain metastases in a post hoc analysis of the ongoing CodeBreaK 100 trial. We present the case of a patient with mutant adenocarcinoma of the lung with active untreated brain metastases with a nearly complete intracranial response only 6 weeks after start of sotorasib illustrating the benefit of sotorasib in patients with active, previously untreated brain metastases in mutated NSCLC.
在正在进行的CodeBreaK 100试验的一项事后分析中，索托拉西布治疗在先前接受过治疗且脑转移稳定的突变型非小细胞肺癌（NSCLC）患者中显示出颅内完全缓解和持续的颅内病情稳定。我们报告了一例患有突变型肺腺癌且伴有未经治疗的活动性脑转移的患者，在开始使用索托拉西布仅6周后就出现了几乎完全的颅内缓解，这说明了索托拉西布对患有活动性、先前未经治疗的突变型NSCLC脑转移患者的益处。
